Thus, it is conceivable that AF improves sensitivity of wild type EGFR NSCLC to TUSC2-erlotinib by mediating increased ROS via inhibition of TXNRD1 in cells rendered less responsive to oxidative stress. This evidence concerns the gene TUSC2 and non-small cell lung carcinoma.